Hershey’s reported a notable increase in sales for its mints and gum, driven in part by the rising use of GLP-1 drugs, according to CEO Kirk Tanner. During the company’s earnings call, Tanner highlighted that retail sales for Ice Breakers, Hershey’s third-largest confection brand, surged over 8% in the last quarter. The connection to GLP-1 medications, which some users report as causing dry mouth and halitosis, suggests a unique market opportunity for mint and gum products.
This trend reflects a broader shift in consumer behavior, as companies like Lindt & Spruengli and Magnum Ice Cream also report increased sales among GLP-1 users, indicating a potential “premium treat substitution effect.” As consumers prioritize higher-quality snacks, Hershey’s quarterly revenue rose by over 10%, despite a slight dip in share prices.
Market professionals should monitor how the GLP-1 drug trend continues to influence consumer preferences, particularly in the premium snack segment, which could reshape competitive dynamics in the confectionery industry.
Source: cnbc.com